We would love to hear your thoughts about our site and services, please take our survey here.
They should get the 180 day extension again.
Hi Jimmy. We are looking at December/January for an update. Accustem have had access to historical breast cancer samples which have been stored at University Hospitals for over a decade. Accustem have been able to use this information to further validate the original StemprintER results.
An update is due shortly from the Accustem collaboration with University Hospital, Cleveland.
I have also considered that a company maybe doing the due diligence in the background on Accustem with a view to a buyout. They have a strategic partnership with Emeritus DX so they would be my favourites.
We know a buyout is the end goal for the company.
Personally, I would rather wait 2-3 years and get taken over when the market is on a bull run.
Commercialisation end of 2024, I’ll take that.
Not sure it’s a good time to be floating at the moment so I’ll stay patient.
Jimmy G, false alarm, pit lane;)
Hopefully next time but tough to hold the gains at the moment in these markets for any stock.
Gentlemen, start your engines;)
You’ll find it’s an issue with the brokers, not the company.
Most brokers have managed to get their house in order.
No scam here, good times ahead ;)
The company have re-strategised to make the cash last for the MS programme/trials. The original Covid trial in Brazil served a purpose but the worldwide need for a long covid therapeutic means the company are right to now steer in this direction.
Just wandering how many of the old crowd from about 3 years ago are still here?
I’m still in! GLA
No crooks here.
Accustem is preparing for the larger Nasdaq market.
TLSA stock has suffered like many other stocks in this market but well positioned for a move upward.
37.72% of the company Cerrone owns. Big holding.
Not ideal lending OKYO money.
He obviously didn’t want to go to the market or do some sort of raise.
ACUT and TLSA are intrinsically linked so absolutely no problem there with playing the game.
Sign of the times.
I imagine things are getting hairy for a lot of companies in the finance department.
Can’t believe the scam word is still being mentioned here lol.
The company have made progress this year, announcing their intention to IPO and opening the door to further cancer prognosis.
There has also been an unbelievable opportunity to trade this and make some serious money in the last 3-4 months. (I haven’t personally traded myself but accumulated).
Surely you wouldn’t buy into a scam when there are so many buying opportunities out there with undervalued companies at the moment?
Accustem volume down this week.
TLSA volume up today, best it’s been for 6 weeks.
Yes this fool is still buying TLSA occasionally haha.
The ACUT buys are looking wise though so helps cushion the blow.
20:1 consolidation. You should have approximately 967 shares in your account now.
Current share price is the equivalent of 27p old money.
Sad but reflected in many other stocks throughout the markets.
Tiziana purchased 1,337,970 shares at $2 a share.
Proceeds to Accustem = $2,675,940.
GC is too savvy a businessman for this not to get over $1.
I’m sure if he needs to wheel out Howard Weiner on Bloomberg to do so he will.
It’s not a million miles away, just one or two decent trading sessions.